Veracyte, Inc. (12V.F)
- Previous Close
18.90 - Open
19.20 - Bid 19.20 x 36100
- Ask 19.30 x 34700
- Day's Range
19.20 - 19.20 - 52 Week Range
17.50 - 26.60 - Volume
40 - Avg. Volume
1 - Market Cap (intraday)
1.468B - Beta (5Y Monthly) 1.65
- PE Ratio (TTM)
-- - EPS (TTM)
-0.86 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
63.17
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
www.veracyte.com815
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 12V.F
Performance Overview: 12V.F
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 12V.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 12V.F
Valuation Measures
Market Cap
1.46B
Enterprise Value
1.28B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.06
Price/Book (mrq)
1.42
Enterprise Value/Revenue
3.70
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.16%
Return on Assets (ttm)
-0.34%
Return on Equity (ttm)
-6.20%
Revenue (ttm)
375.47M
Net Income Avi to Common (ttm)
-68.18M
Diluted EPS (ttm)
-0.86
Balance Sheet and Cash Flow
Total Cash (mrq)
209.19M
Total Debt/Equity (mrq)
1.26%
Levered Free Cash Flow (ttm)
36.61M